<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01408173</url>
  </required_header>
  <id_info>
    <org_study_id>NPC-11-1</org_study_id>
    <nct_id>NCT01408173</nct_id>
  </id_info>
  <brief_title>Clinical Study of Caffeine for Apnea of Prematurity</brief_title>
  <official_title>A Phase III Clinical Study of NPC-11 in the Treatment of Apnea of Prematurity. - Investigation of Safety, Efficacy and Pharmacokinetics of Caffeine Citrate -</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nobelpharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nobelpharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present Phase III study is to evaluate the safety, efficacy and
      pharmacokinetics of Caffeine Citrate for treatment of apnea of prematurity in Japan.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success rates for controlling of apnea episode in each observation day (at least 50% reduction of apnea episodes from baseline)</measure>
    <time_frame>1, 2, 3, 4, 5, 6,7, 8, 9 and 10 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change of frequency of apnea episode from baseline in each observation day</measure>
    <time_frame>1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to event：Days until next events occurred</measure>
    <time_frame>1 to 10 day</time_frame>
    <description>Time to event：Days until next events occurred.
The definition of events are, Not at least 50% reduction of apnea episode Not improving the frequency of episode from baseline Needs mechanical/bag valve mask ventilation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of average duration time of apnea episode from baseline in each observation day</measure>
    <time_frame>1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of lowest oxygen saturation during apnea episodes from baseline in each observation day</measure>
    <time_frame>1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of less than 85% oxygen saturation during apnea episodes in each observation day</measure>
    <time_frame>1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 day</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Apnea of Prematurity</condition>
  <arm_group>
    <arm_group_label>NPC-11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loading Dose (Day 1): Caffeine citrate 20 mg/kg body weight will be administered intravenously using a syringe infusion pump over 30 minutes.
Maintenance Dose (Day 2～Day 10): After an interval 24 hours, caffeine citrate 5 mg/kg body weight will be administered intravenously (over 10 minutes) or orally if the patients will be able to receive oral administration once a day. The maintenance dose can be increased to a maximum 10 mg/kg caffeine citrate once a day if apnea persists.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPC-11 for intravenous or oral administration.</intervention_name>
    <description>NPC-11, Each vial (3mL) contains 60 mg caffeine citrate (equivalent to 30mg caffeine).</description>
    <arm_group_label>NPC-11</arm_group_label>
    <other_name>caffeine citrate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postconceptional age between 28 weeks and 33 weeks, and over 24 hours after birth.

          -  At least 6 episodes of apnea (&gt;20 seconds in duration) in 24 hours.

          -  Signed written informed consent from parent(s) or legal guardian(s).

        Exclusion Criteria:

          -  Apnea due to: hypoxic-ischemic encephalopathy, meningitis, seizures, Grade III or IV
             intracranial hemorrhage, CNS depression from drugs administered to the mother during
             delivery, periventricular leukomalacia, pneumonia which does not improve even if it
             treats, hemoglobin&lt; 10 g/dL, sepsis, shock which does not improve even if it treats,
             blood pH&lt;7.2 on 2 consecutive determinations in spite of correction, serum calcium
             concentration &lt;7.0 mg/dL which does not improve even if it treats, serum glucose
             concentration &lt;4.0 mg/dL which does not improve even if it treats, congestive heart
             failure, symptomatic patent ductus arteriosus, rectal temperature＞38.5 °C on 2
             consecutive readings, rectal temperature&lt; 35 °C on 2 consecutive readings, obstructive
             apnea.

          -  Blood urea nitrogen &gt;20 mg/dL, serum creatinine &gt;1.5 mg/dL.

          -  Serum AST or ALT &gt;3 times the upper limit of normal.

          -  Requirement of mechanically-assisted ventilation ( containing nasal CPAP, nasal DPAP).

          -  Previous treatment with methylxanthines within 7 days prior to study enrollment.

          -  Previous treatment with H2 antagonists (i.e., cimetidine or ranitidine) within 7 days
             prior to study enrollment.

          -  Receiving or experiencing the effects of CNS-active medication at the time of
             enrollment.

          -  Participant of other clinical trial within 6 months.

          -  Inappropriate to enter this clinical trial judged by the investigator in charge.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>28 Weeks</minimum_age>
    <maximum_age>33 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susumu Itoh, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kagawa University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fujita Health University Hospital</name>
      <address>
        <city>Kutsukake</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Medical Center and Research Institute for Maternal and Child Health</name>
      <address>
        <city>Izumi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Metropolitan Children's Medical Center</name>
      <address>
        <city>Fuchu</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2011</study_first_submitted>
  <study_first_submitted_qc>August 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2011</study_first_posted>
  <last_update_submitted>October 29, 2013</last_update_submitted>
  <last_update_submitted_qc>October 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>caffeine</keyword>
  <keyword>apnea</keyword>
  <keyword>prematurity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Caffeine citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

